Slingshot members are tracking this corporate initiative:
Bristol-Myers Squibb (BMY) Enters Collaboration Agreement with Calithera Biosciences (CALA) to Evaluating Opdivo + CB-839 in Clear Cell Renal Cell Carcinoma
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Dec 21, 2016 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2019
Don’t see a project related to the strategic initiative you care about?
Related Keywords Collaboration Agreement, Opdivo, Cb-839, Clear Cell Renal Cell Carcinoma